Rita Nanda, MD
- Researches new treatments for breast cancer, with a focus on triple-negative disease
Rita Nanda, MD, is an associate professor of medicine and director of the breast medical oncology program at The University of Chicago. Her research interests include identifying new treatments for breast cancer, with a focus on triple-negative disease.
She leads the University of Chicago’s clinical and translational breast cancer research efforts, and serves as a principal investigator for the Translational Breast Cancer Research Consortium (TBCRC) and the ISPY2 Clinical Trial Network. She is a member of several professional organizations, including the American Society of Clinical Oncology, the American Association of Cancer Research, and the Society for Immunotherapy of Cancer.
Dr. Nanda has authored many scientific publications and book chapters, including one of the first reports of immune checkpoint inhibitor therapy for triple-negative breast cancer. She presents her research often at national and international conferences. She has earned several awards, including the 2014 NCI Cancer Clinical Investigator Team Leadership Award.
Pembrolizumab approved for high-risk triple-negative breast cancer
The FDA approved the use of pembrolizumab (Keytruda) to treat some early-stage, triple-negative breast cancers, marking the first time an immunotherapy medicine has been approved for use in early-stage breast cancer.